Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598291 | 0.93 | GPR119 (0.55) | GPR119HDAC4MEN1KMT2AABL1 | |
| SCHEMBL13598277 | 0.91 | GPR119 (0.54) | GPR119HDAC4ABL1RIN1SPHK1 | |
| SCHEMBL4416333 | 0.90 | GPR119 (0.54) | GPR119HDAC4HDAC6SPHK1SPHK2 | |
| SCHEMBL4415980 | 0.89 | GPR119 (0.53) | GPR119HDAC4HDAC6SPHK1SPHK2 | |
| SCHEMBL4415700 | 0.88 | GPR119 (0.58) | GPR119HDAC4HDAC6KMT2ACETP | |
| SCHEMBL4415562 | 0.88 | GPR119 (0.58) | GPR119HDAC4HDAC6CETP | |
| SCHEMBL4412797 | 0.88 | GPR119 (0.57) | GPR119HDAC4HDAC6SPHK1SPHK2 | |
| SCHEMBL4414106 | 0.87 | GPR119 (0.56) | GPR119HDAC4HDAC6CETP | |
| SCHEMBL13598306 | 0.87 | HDAC4 (0.57) | GPR119HDAC4HDAC6KMT2ACETP | |
| SCHEMBL4426184 | 0.87 | GPR119 (0.51) | GPR119HDAC4HDAC6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HDAC4 2550/4885HDAC2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.